Treatment-Interval Changes in Serum Levels of Albumin and Histidine Correlated with Treatment Interruption in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma Completing Chemoradiotherapy under Recommended Calorie and Protein Provision
We investigated risk factors for treatment interruption (TI) in patients with locally advanced head and neck squamous-cell carcinoma (LAHNSCC) following concurrent chemoradiotherapy (CCRT), under the provision of recommended calorie and protein intake; we also evaluated the associations between clin...
Gespeichert in:
| Veröffentlicht in: | Cancers 2022-06, Vol.14 (13), p.3112 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 13 |
| container_start_page | 3112 |
| container_title | Cancers |
| container_volume | 14 |
| creator | Wang, Chao-Hung Ling, Hang Huong Liu, Min-Hui Pan, Yi-Ping Chang, Pei-Hung Lin, Yu-Ching Chou, Wen-Chi Peng, Chia-Lin Yeh, Kun-Yun |
| description | We investigated risk factors for treatment interruption (TI) in patients with locally advanced head and neck squamous-cell carcinoma (LAHNSCC) following concurrent chemoradiotherapy (CCRT), under the provision of recommended calorie and protein intake; we also evaluated the associations between clinicopathological variables, calorie and protein supply, nutrition–inflammation biomarkers (NIBs), total body composition change (TBC), and a four-serum-amino-acid metabolite panel (histidine, leucine, ornithine, and phenylalanine) among these patients. Patients with LAHNSCC who completed the entire planned CCRT course and received at least 25 kcal/kg/day and 1 g of protein/kg/day during CCRT were prospectively recruited. Clinicopathological variables, anthropometric data, blood NIBs, CCRT-related factors, TBC data, and metabolite panels before and after treatment were collected; 44 patients with LAHNSCC were enrolled. Nine patients (20.4%) experienced TIs. Patients with TIs experienced greater reductions in hemoglobin, serum levels of albumin, uric acid, histidine, and appendicular skeletal mass, and suffered from more grade 3/4 toxicities than those with no TI. Neither increased daily calorie supply (≥30 kcal/kg/day) nor feeding tube placement was correlated with TI. Multivariate analysis showed that treatment-interval changes in serum albumin and histidine levels, but not treatment toxicity, were independently associated with TI. Thus, changes in serum levels of albumin and histidine over the treatment course could cause TI in patients with LAHNSCC following CCRT. |
| doi_str_mv | 10.3390/cancers14133112 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9264877</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2687717820</sourcerecordid><originalsourceid>FETCH-LOGICAL-c398t-bd2aa162c3caafea8262ca9b2bad297d484c57917507096a0024e0f3c0eb0c253</originalsourceid><addsrcrecordid>eNpdks1vEzEQxVcIRKvQM1dLXLiEer2b_bggRStKK0VQ0XJezdqTxMUf6dgblL8evElVQX3xaPz085unybL3Of9UFC2_lOAkUsjLvCjyXLzKzgWvxbyq2vL1P_VZdhHCA08nyeqqfpudFYuGl01Tnmd_7gkhWnRxfuMi0h4M67bgNhiYduwOabRshXs0gfk1W5phtKkPTrFrHaJW2iHrPBEaiKjYbx237JnJjkwad1F7N_FuIerUDyfdyksw5sCWaj-NkpAI6sj-hvIXu3scwfoxsA5NcgUktfMW0nd2ZzBqt0lW0XoCpX3cIsHuwEankNgPlN4mBypBOzCeNB65t-QjTj7I73VIpt5lb9ZgAl483bPs59WX--56vvr-9aZbruayaJs4H5QAyCshCwmwRmhEqqEdxABKtLUqm1Iu6javF7zmbQWcixL5upAcBy7Fophln0_c3ThYVDKFQGD6HWkLdOg96P7_F6e3_cbv-1ZUZVPXCfDxCUD-ccQQe6uDTMGAw5RRL6qkyutG8CT98EL64EdyabxJtWirVqSNmWWXJ5UkHwLh-tlMzvtpv_oX-1X8BZqDyr8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2685969213</pqid></control><display><type>article</type><title>Treatment-Interval Changes in Serum Levels of Albumin and Histidine Correlated with Treatment Interruption in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma Completing Chemoradiotherapy under Recommended Calorie and Protein Provision</title><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Wang, Chao-Hung ; Ling, Hang Huong ; Liu, Min-Hui ; Pan, Yi-Ping ; Chang, Pei-Hung ; Lin, Yu-Ching ; Chou, Wen-Chi ; Peng, Chia-Lin ; Yeh, Kun-Yun</creator><creatorcontrib>Wang, Chao-Hung ; Ling, Hang Huong ; Liu, Min-Hui ; Pan, Yi-Ping ; Chang, Pei-Hung ; Lin, Yu-Ching ; Chou, Wen-Chi ; Peng, Chia-Lin ; Yeh, Kun-Yun</creatorcontrib><description>We investigated risk factors for treatment interruption (TI) in patients with locally advanced head and neck squamous-cell carcinoma (LAHNSCC) following concurrent chemoradiotherapy (CCRT), under the provision of recommended calorie and protein intake; we also evaluated the associations between clinicopathological variables, calorie and protein supply, nutrition–inflammation biomarkers (NIBs), total body composition change (TBC), and a four-serum-amino-acid metabolite panel (histidine, leucine, ornithine, and phenylalanine) among these patients. Patients with LAHNSCC who completed the entire planned CCRT course and received at least 25 kcal/kg/day and 1 g of protein/kg/day during CCRT were prospectively recruited. Clinicopathological variables, anthropometric data, blood NIBs, CCRT-related factors, TBC data, and metabolite panels before and after treatment were collected; 44 patients with LAHNSCC were enrolled. Nine patients (20.4%) experienced TIs. Patients with TIs experienced greater reductions in hemoglobin, serum levels of albumin, uric acid, histidine, and appendicular skeletal mass, and suffered from more grade 3/4 toxicities than those with no TI. Neither increased daily calorie supply (≥30 kcal/kg/day) nor feeding tube placement was correlated with TI. Multivariate analysis showed that treatment-interval changes in serum albumin and histidine levels, but not treatment toxicity, were independently associated with TI. Thus, changes in serum levels of albumin and histidine over the treatment course could cause TI in patients with LAHNSCC following CCRT.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers14133112</identifier><identifier>PMID: 35804884</identifier><language>eng</language><publisher>Basel: MDPI AG</publisher><subject>Albumin ; Amino acids ; Body composition ; Breakdowns ; Calories ; Cancer therapies ; Chemoradiotherapy ; Chemotherapy ; Clinical outcomes ; Compliance ; Disease ; Head & neck cancer ; Head and neck carcinoma ; Heart failure ; Hemoglobin ; Histidine ; Holidays & special occasions ; Metabolism ; Metabolites ; Multivariate analysis ; Nutrition ; Ornithine ; Patients ; Phenylalanine ; Proteins ; Radiation therapy ; Risk factors ; Serum levels ; Squamous cell carcinoma ; Surgery ; Toxicity ; Uric acid</subject><ispartof>Cancers, 2022-06, Vol.14 (13), p.3112</ispartof><rights>2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 by the authors. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c398t-bd2aa162c3caafea8262ca9b2bad297d484c57917507096a0024e0f3c0eb0c253</citedby><cites>FETCH-LOGICAL-c398t-bd2aa162c3caafea8262ca9b2bad297d484c57917507096a0024e0f3c0eb0c253</cites><orcidid>0000-0001-5468-4354 ; 0000-0001-5572-7897</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264877/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264877/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids></links><search><creatorcontrib>Wang, Chao-Hung</creatorcontrib><creatorcontrib>Ling, Hang Huong</creatorcontrib><creatorcontrib>Liu, Min-Hui</creatorcontrib><creatorcontrib>Pan, Yi-Ping</creatorcontrib><creatorcontrib>Chang, Pei-Hung</creatorcontrib><creatorcontrib>Lin, Yu-Ching</creatorcontrib><creatorcontrib>Chou, Wen-Chi</creatorcontrib><creatorcontrib>Peng, Chia-Lin</creatorcontrib><creatorcontrib>Yeh, Kun-Yun</creatorcontrib><title>Treatment-Interval Changes in Serum Levels of Albumin and Histidine Correlated with Treatment Interruption in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma Completing Chemoradiotherapy under Recommended Calorie and Protein Provision</title><title>Cancers</title><description>We investigated risk factors for treatment interruption (TI) in patients with locally advanced head and neck squamous-cell carcinoma (LAHNSCC) following concurrent chemoradiotherapy (CCRT), under the provision of recommended calorie and protein intake; we also evaluated the associations between clinicopathological variables, calorie and protein supply, nutrition–inflammation biomarkers (NIBs), total body composition change (TBC), and a four-serum-amino-acid metabolite panel (histidine, leucine, ornithine, and phenylalanine) among these patients. Patients with LAHNSCC who completed the entire planned CCRT course and received at least 25 kcal/kg/day and 1 g of protein/kg/day during CCRT were prospectively recruited. Clinicopathological variables, anthropometric data, blood NIBs, CCRT-related factors, TBC data, and metabolite panels before and after treatment were collected; 44 patients with LAHNSCC were enrolled. Nine patients (20.4%) experienced TIs. Patients with TIs experienced greater reductions in hemoglobin, serum levels of albumin, uric acid, histidine, and appendicular skeletal mass, and suffered from more grade 3/4 toxicities than those with no TI. Neither increased daily calorie supply (≥30 kcal/kg/day) nor feeding tube placement was correlated with TI. Multivariate analysis showed that treatment-interval changes in serum albumin and histidine levels, but not treatment toxicity, were independently associated with TI. Thus, changes in serum levels of albumin and histidine over the treatment course could cause TI in patients with LAHNSCC following CCRT.</description><subject>Albumin</subject><subject>Amino acids</subject><subject>Body composition</subject><subject>Breakdowns</subject><subject>Calories</subject><subject>Cancer therapies</subject><subject>Chemoradiotherapy</subject><subject>Chemotherapy</subject><subject>Clinical outcomes</subject><subject>Compliance</subject><subject>Disease</subject><subject>Head & neck cancer</subject><subject>Head and neck carcinoma</subject><subject>Heart failure</subject><subject>Hemoglobin</subject><subject>Histidine</subject><subject>Holidays & special occasions</subject><subject>Metabolism</subject><subject>Metabolites</subject><subject>Multivariate analysis</subject><subject>Nutrition</subject><subject>Ornithine</subject><subject>Patients</subject><subject>Phenylalanine</subject><subject>Proteins</subject><subject>Radiation therapy</subject><subject>Risk factors</subject><subject>Serum levels</subject><subject>Squamous cell carcinoma</subject><subject>Surgery</subject><subject>Toxicity</subject><subject>Uric acid</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdks1vEzEQxVcIRKvQM1dLXLiEer2b_bggRStKK0VQ0XJezdqTxMUf6dgblL8evElVQX3xaPz085unybL3Of9UFC2_lOAkUsjLvCjyXLzKzgWvxbyq2vL1P_VZdhHCA08nyeqqfpudFYuGl01Tnmd_7gkhWnRxfuMi0h4M67bgNhiYduwOabRshXs0gfk1W5phtKkPTrFrHaJW2iHrPBEaiKjYbx237JnJjkwad1F7N_FuIerUDyfdyksw5sCWaj-NkpAI6sj-hvIXu3scwfoxsA5NcgUktfMW0nd2ZzBqt0lW0XoCpX3cIsHuwEankNgPlN4mBypBOzCeNB65t-QjTj7I73VIpt5lb9ZgAl483bPs59WX--56vvr-9aZbruayaJs4H5QAyCshCwmwRmhEqqEdxABKtLUqm1Iu6javF7zmbQWcixL5upAcBy7Fophln0_c3ThYVDKFQGD6HWkLdOg96P7_F6e3_cbv-1ZUZVPXCfDxCUD-ccQQe6uDTMGAw5RRL6qkyutG8CT98EL64EdyabxJtWirVqSNmWWXJ5UkHwLh-tlMzvtpv_oX-1X8BZqDyr8</recordid><startdate>20220624</startdate><enddate>20220624</enddate><creator>Wang, Chao-Hung</creator><creator>Ling, Hang Huong</creator><creator>Liu, Min-Hui</creator><creator>Pan, Yi-Ping</creator><creator>Chang, Pei-Hung</creator><creator>Lin, Yu-Ching</creator><creator>Chou, Wen-Chi</creator><creator>Peng, Chia-Lin</creator><creator>Yeh, Kun-Yun</creator><general>MDPI AG</general><general>MDPI</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-5468-4354</orcidid><orcidid>https://orcid.org/0000-0001-5572-7897</orcidid></search><sort><creationdate>20220624</creationdate><title>Treatment-Interval Changes in Serum Levels of Albumin and Histidine Correlated with Treatment Interruption in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma Completing Chemoradiotherapy under Recommended Calorie and Protein Provision</title><author>Wang, Chao-Hung ; Ling, Hang Huong ; Liu, Min-Hui ; Pan, Yi-Ping ; Chang, Pei-Hung ; Lin, Yu-Ching ; Chou, Wen-Chi ; Peng, Chia-Lin ; Yeh, Kun-Yun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c398t-bd2aa162c3caafea8262ca9b2bad297d484c57917507096a0024e0f3c0eb0c253</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Albumin</topic><topic>Amino acids</topic><topic>Body composition</topic><topic>Breakdowns</topic><topic>Calories</topic><topic>Cancer therapies</topic><topic>Chemoradiotherapy</topic><topic>Chemotherapy</topic><topic>Clinical outcomes</topic><topic>Compliance</topic><topic>Disease</topic><topic>Head & neck cancer</topic><topic>Head and neck carcinoma</topic><topic>Heart failure</topic><topic>Hemoglobin</topic><topic>Histidine</topic><topic>Holidays & special occasions</topic><topic>Metabolism</topic><topic>Metabolites</topic><topic>Multivariate analysis</topic><topic>Nutrition</topic><topic>Ornithine</topic><topic>Patients</topic><topic>Phenylalanine</topic><topic>Proteins</topic><topic>Radiation therapy</topic><topic>Risk factors</topic><topic>Serum levels</topic><topic>Squamous cell carcinoma</topic><topic>Surgery</topic><topic>Toxicity</topic><topic>Uric acid</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Chao-Hung</creatorcontrib><creatorcontrib>Ling, Hang Huong</creatorcontrib><creatorcontrib>Liu, Min-Hui</creatorcontrib><creatorcontrib>Pan, Yi-Ping</creatorcontrib><creatorcontrib>Chang, Pei-Hung</creatorcontrib><creatorcontrib>Lin, Yu-Ching</creatorcontrib><creatorcontrib>Chou, Wen-Chi</creatorcontrib><creatorcontrib>Peng, Chia-Lin</creatorcontrib><creatorcontrib>Yeh, Kun-Yun</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Chao-Hung</au><au>Ling, Hang Huong</au><au>Liu, Min-Hui</au><au>Pan, Yi-Ping</au><au>Chang, Pei-Hung</au><au>Lin, Yu-Ching</au><au>Chou, Wen-Chi</au><au>Peng, Chia-Lin</au><au>Yeh, Kun-Yun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment-Interval Changes in Serum Levels of Albumin and Histidine Correlated with Treatment Interruption in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma Completing Chemoradiotherapy under Recommended Calorie and Protein Provision</atitle><jtitle>Cancers</jtitle><date>2022-06-24</date><risdate>2022</risdate><volume>14</volume><issue>13</issue><spage>3112</spage><pages>3112-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>We investigated risk factors for treatment interruption (TI) in patients with locally advanced head and neck squamous-cell carcinoma (LAHNSCC) following concurrent chemoradiotherapy (CCRT), under the provision of recommended calorie and protein intake; we also evaluated the associations between clinicopathological variables, calorie and protein supply, nutrition–inflammation biomarkers (NIBs), total body composition change (TBC), and a four-serum-amino-acid metabolite panel (histidine, leucine, ornithine, and phenylalanine) among these patients. Patients with LAHNSCC who completed the entire planned CCRT course and received at least 25 kcal/kg/day and 1 g of protein/kg/day during CCRT were prospectively recruited. Clinicopathological variables, anthropometric data, blood NIBs, CCRT-related factors, TBC data, and metabolite panels before and after treatment were collected; 44 patients with LAHNSCC were enrolled. Nine patients (20.4%) experienced TIs. Patients with TIs experienced greater reductions in hemoglobin, serum levels of albumin, uric acid, histidine, and appendicular skeletal mass, and suffered from more grade 3/4 toxicities than those with no TI. Neither increased daily calorie supply (≥30 kcal/kg/day) nor feeding tube placement was correlated with TI. Multivariate analysis showed that treatment-interval changes in serum albumin and histidine levels, but not treatment toxicity, were independently associated with TI. Thus, changes in serum levels of albumin and histidine over the treatment course could cause TI in patients with LAHNSCC following CCRT.</abstract><cop>Basel</cop><pub>MDPI AG</pub><pmid>35804884</pmid><doi>10.3390/cancers14133112</doi><orcidid>https://orcid.org/0000-0001-5468-4354</orcidid><orcidid>https://orcid.org/0000-0001-5572-7897</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2022-06, Vol.14 (13), p.3112 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9264877 |
| source | PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Albumin Amino acids Body composition Breakdowns Calories Cancer therapies Chemoradiotherapy Chemotherapy Clinical outcomes Compliance Disease Head & neck cancer Head and neck carcinoma Heart failure Hemoglobin Histidine Holidays & special occasions Metabolism Metabolites Multivariate analysis Nutrition Ornithine Patients Phenylalanine Proteins Radiation therapy Risk factors Serum levels Squamous cell carcinoma Surgery Toxicity Uric acid |
| title | Treatment-Interval Changes in Serum Levels of Albumin and Histidine Correlated with Treatment Interruption in Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma Completing Chemoradiotherapy under Recommended Calorie and Protein Provision |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T01%3A14%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment-Interval%20Changes%20in%20Serum%20Levels%20of%20Albumin%20and%20Histidine%20Correlated%20with%20Treatment%20Interruption%20in%20Patients%20with%20Locally%20Advanced%20Head%20and%20Neck%20Squamous%20Cell%20Carcinoma%20Completing%20Chemoradiotherapy%20under%20Recommended%20Calorie%20and%20Protein%20Provision&rft.jtitle=Cancers&rft.au=Wang,%20Chao-Hung&rft.date=2022-06-24&rft.volume=14&rft.issue=13&rft.spage=3112&rft.pages=3112-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers14133112&rft_dat=%3Cproquest_pubme%3E2687717820%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2685969213&rft_id=info:pmid/35804884&rfr_iscdi=true |